Efficacy and Toxicity Profile of Carboplatin/Gemcitabine Chemotherapy in Locally Advanced or Metastatic Biliary Tract Cancer: A Single UK Centre Experience
Retrospective analysis shows survival rates in patients with biliary tract cancer, suggesting carboplatin/gemcitabine as a feasible alternative treatment.
Key Points
The median overall survival was 8.97 months, indicating potential but limited efficacy for this chemotherapy regimen.
Tumour control rate was achieved in 70% of cases, reflecting a reasonable response in the treated population.
Retrospective analysis of patient data from a single centre evaluated survival outcomes and toxicities.
Common haematological toxicities included thrombocytopenia (63.7%) and neutropenia (48.5%), necessitating close monitoring.